Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity

Blood

Volumn 107, Issue 6, 2006, Pages 2384-2391

  Cahuzac, Nathalie ^b   Baum, Wiebke ^b   Kirkin, Vladimir ^b   Conchonaud, Fabien ^b   Wawrezinieck, Laure ^b   Marguet, Didier ^b   Janssen, Ottmar ^b   Zörnig, Martin ^b   Hueber, Anne Odile ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL OXIDASE; FAS LIGAND; PROLINE; PROTEIN SH3; SPHINGOLIPID;

ARTICLE; BINDING SITE; CELL DEATH; CELL MEMBRANE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID RAFT; MEMBRANE STRUCTURE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION;

EID: 33644762884     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2883     Document Type: Article

References (58)

1. Janssen O, Qian J, Linkermann A, Kabelitz D. CD95 ligand - death factor and costimulatory molecule? Cell Death Differ. 2003;10:1215-1225.
2. Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428-1440.
3. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579-5588.
4. Linkermann A, Qian J, Kabelitz D, Janssen O. The Fas ligand as a cell death factor and signal transducer. Signal Transduction. 2003;3:33-46.
5. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 1995;154:3806-3813.
6. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181:71-77.
7. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370:650-652.
8. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
9. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
10. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
11. Karray S, Kress C, Cuvellier S, et al. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol. 2004;172:2118-2125.
12. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317.
13. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969-976.
14. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet. 1995;11:294-300.
15. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
16. Nose M, Nishihara M, Kamogawa J, Terada M, Nakatsuru S. Genetic basis of autoimmune disease in MRL/lpr mice: dissection of the complex pathological manifestations and their susceptibility loci. Rev Immunogenet. 2000;2:154-164.
17. Jackson CE, Puck JM. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr. 1999;11:521-527.
18. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341-1348.
19. Adam-Klages S, Adam D, Janssen O, Kabelitz D. Death receptors and caspases: role in proliferation, cell death and autoimmunity. Immunol Res. In press.
20. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol. 1999;163:4335-4341.
21. Blott EJ, Bossi G, Clark R, Zvelebil M, Griffiths GM. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci. 2001;114:2405-2416.
22. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol. 2002;3:122-131.
23. Suzuki I, Fink PJ. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc Natl Acad Sci U S A. 2000;97:1707-1712.
24. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med. 1998;187:123-128.
25. Suzuki I, Martin S, Boursalian TE, Beers C, Fink PJ. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J Immunol. 2000;165:5537-5543.
26. Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med. 1998;4:1377-1382.
27. Ulisse S, Cinque B, Silvano G, et al. Erk-dependent cytosolic phospholipase A2 activity is induced by CD95 ligand cross-linking in the mouse derived Sertoli cell line TM4 and is required to trigger apoptosis in CD95 bearing cells. Cell Death Differ. 2000;7:916-924.
28. Watts AD, Hunt NH, Wanigasekara Y, et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in "reverse signalling." EMBO J. 1999;18:2119-2126.
29. Morris R, Cox H, Mombelli E, Quinn PJ. Rafts, little caves and large potholes: how lipid structure interacts with membrane proteins to create functionally diverse membrane environments. Subcell Biochem. 2004;37:35-118.
30. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569-572.
31. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem. 2000;275:17221-17224.
32. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31-39.
33. Hueber AO, Bernard AM, Hérincs Z, Couzinet A, He HT. An essential role of membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep. 2002;3:190-196.
34. Hueber AO. Role of membrane microdomain rafts in TNFR-mediated signal transduction. Cell Death Differ. 2003;10:7-9.
35. Scheel-Toellner D, Wang K, Singh R, et al. The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun. 2002;297:876-879.
36. Eramo A, Sargiacomo M, Ricci-Vitiani L, et al. CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur J Immunol. 2004;34:1930-1940.
37. Grassme H, Jekle A, Riehle A, et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem. 2001;276:20589-20596.
38. ++-independent T cell-mediated cytotoxicity. J Exp Med. 1993;177:195-200.
39. Izquierdo M, Downward J, Graves JD, Cantrell DA. Role of protein kinase C in T-cell antigen receptor regulation of p21ras: evidence that two p21ras regulatory pathways coexist in T cells. Mol Cell Biol. 1992;12:3305-3312.
40. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652-658.
41. Pagano RE, Martin OC. A series of fluorescent N-acylsphingosines: synthesis, physical properties, and studies in cultured cells. Biochemistry. 1988;27:4439-4445.
42. Wawrezinieck L, Lenne P-F, Marguet D, Rigneault H. Fluorescence correlation spectroscopy to determine diffusion laws: application to live cell membranes. Proc SPIE. 2004;5462:92-102.
43. Wawrezinieck L, Rigneault H, Marguet D, Lenne PF. Fluorescence correlation spectroscopy diffusion laws to probe the submicron cell membrane organization. Biophys J. 2005;89:4029-4042.
44. Drevot P, Langlet C, Guo XJ, et al. TCR signal initiation machinery is pre-assembled and activated in a subset of membrane rafts. EMBO J. 2002;21:1899-1908.
45. Madore N, Smith KL, Graham CH, et al. Functionally different GPI proteins are organized in different domains on the neuronal surface. EMBO J. 1999;18:6917-6926.
46. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J. 2004;378:281-292.
47. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol. 1998;141:929-942.
48. Melkonian KA, Ostermeyer AG, Chen JZ, Roth MG, Brown DA. Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts: many raft proteins are acylated, while few are prenylated. J Biol Chem. 1999;274:3910-3917.
49. Kahya N, Scherfeld D, Bacia K, Schwille P. Lipid domain formation and dynamics in giant unilamellar vesicles explored by fluorescence correlation spectroscopy. J Struct Biol. 2004;147:77-89.
50. Gosch M, Rigler R. Fluorescence correlation spectroscopy of molecular motions and kinetics. Adv Drug Deliv Rev. 2005;57:169-190.
51. Baum W, Kirkin V, Mateus Fernandez SB, et al. Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL. J Biol Chem. 2005;280:40012-40024.
52. Reinehr R, Graf D, Fischer R, Schliess F, Haussinger D. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis. Hepatology. 2002;36:602-614.
53. He HT, Lellouch A, Marguet D. Lipid rafts and the initiation of T cell receptor signaling. Semin Immunol. 2005;17:23-33.
54. Henkler F, Behrle E, Dennehy KM, et al. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J Cell Biol. 2005;168:1087-1098.
55. Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem. 2005;280:11641-11647.
56. Lalor D, Liu P, Hayashi J. Fas ligand is enriched in the caveolae membrane domains of thymic epithelial cells. Cell Immunol. 2004;230:10-16.
57. Millan J, Puertollano R, Fan L, Alonso MA. Caveolin and MAL, two protein components of internal detergent-insoluble membranes, are in distinct lipid microenvironments in MDCK cells. Biochem Biophys Res Commun. 1997;233:707-712.
58. Trambas C, Gallo F, Pende D, et al. A single amino acid change, A91V, lead to conformational changes which can impair processing to the active form of perforin. Blood. 2005;106:932-937.